Drug intelligence / Profile preview

BRC-OA

Development stage: Phase 2
Lead developer: Britecyte
Administration: Intraarticular

Overview

BRC-OA is a cryopreserved, devitalized human adipose tissue allograft developed by Britecyte, Inc. for the treatment of pain associated with osteoarthritis, particularly of the knee. Unlike live cell therapies, BRC-OA consists of a devitalized particulate that preserves the natural tissue architecture, extracellular matrix (ECM), and endogenous signaling molecules of human adipose tissue. It is designed to provide structural support and a regenerative microenvironment when injected intra-articularly, aiming to alleviate pain and potentially improve joint function in patients with mild to severe osteoarthritis. The product is currently being evaluated in Phase 1/2a clinical trials to assess its safety and initial efficacy.

Other names: cryopreserved devitalized adipose tissue allograft

Beyond the preview

Go deeper on BRC-OA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRC-OA.

Explore the full profile